title: Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care.
abstract: BACKGROUND
  The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established.
  
  
  METHODS
  Fifty-three cognitively impaired patients with clinical F18-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics andttest were used to compare demographic characteristics and clinical outcomes as appropriate.
  
  
  RESULTS
  Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group.
  
  
  CONCLUSIONS
  The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases.
authors.affiliation: Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Radiological Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA.
authors.forename: Liana G
authors.initials: LG
authors.lastname: Apostolova
authors.affiliation: Department of Neurology, Cedar-Sinai Medical Center, Los Angeles, CA, USA.
authors.forename: Janelle M
authors.initials: JM
authors.lastname: Haider
authors.affiliation: Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA.
authors.forename: Naira
authors.initials: N
authors.lastname: Goukasian
authors.affiliation: Memory & Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
authors.forename: Gil D
authors.initials: GD
authors.lastname: Rabinovici
authors.affiliation: Inserm, EPHE, Université de Caen Basse-Normandie, Unité de Recherche 1077, Caen, France.
authors.forename: Gael
authors.initials: G
authors.lastname: Chételat
authors.affiliation: Department of Neurology, Keck School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
authors.forename: John M
authors.initials: JM
authors.lastname: Ringman
authors.affiliation: Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA.
authors.forename: Sarah
authors.initials: S
authors.lastname: Kremen
authors.affiliation: Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, CA, USA.
authors.forename: Joshua D
authors.initials: JD
authors.lastname: Grill
authors.affiliation: Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA.
authors.forename: Lucas
authors.initials: L
authors.lastname: Restrepo
authors.affiliation: Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA; Department of Psychiatry, University of California Los Angeles, Los Angeles, CA, USA.
authors.forename: Mario F
authors.initials: MF
authors.lastname: Mendez
authors.affiliation: Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Silverman
keywords: Alzheimer's disease (AD); Amyloid; Appropriate use criteria (AUC); Mild cognitive impairment (MCI); Positron emission tomography (PET)